Filing Flows › Cronos Group (CRON) › Guidance & outlook
Cronos Group (CRON) guidance and outlook
Cronos Group's 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- • our ability or plans to identify, develop, commercialize or expand our technology and research and development (“R&D”) initiatives in cannabinoids, or the success thereof;
- • the anticipated benefits and impact of Altria Group, Inc.’s investment in the Company (the “Altria Investment”), pursuant to a subscription agreement dated December 7, 2018;
- Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods .
- Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.
- Beginning in 2025, the Company modified the composition of Adjusted EBITDA to exclude the impact of the provision for expected credit losses recognized under ASC 326 with respect to the High Tide Loan (see Note 4 “ Loans Receivable, net ” to the condensed consolidated financial statements under Item 1 of this Quarterly Report for further information).
- Beginning in the third quarter of 2026, the Company modified the composition of Adjusted EBITDA to exclude the impact of the provision for expected credit losses recognized under ASC 326 related to the Company’s guaranteed investment certificates held in cash equivalents, short-term investments, and non-current interest-bearing deposits (see Note 1 “ Background, Basis of Presentation, and Summary of Significant…
- (viii) For the three and nine months ended September 30, 2026 and 2025, change in allowance for credit loss on non-operating loan and interest-bearing deposits related primarily to the allowance recognized on the High Tide loan receivable, as described in Note 4, “Loans Receivable, net.” The three and nine months ended September 30, 2026, also include expected credit losses on the Company’s cash equivalents,…
Cronos Group's latest quarter
Cronos Group, Q3 2026: revenue $83.9M (+72% year over year), operating margin 10.8%, net earnings $13.8M, operating cash flow $34.3M. The chart follows the revenue to costs, profit and cash.
Questions
What does Cronos Group expect?
• our ability or plans to identify, develop, commercialize or expand our technology and research and development (“R&D”) initiatives in cannabinoids, or the success thereof; • the anticipated benefits and impact of Altria Group, Inc.’s investment in the Company (the “Altria Investment”), pursuant to a subscription agreement dated December 7, 2018; Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods .
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.